{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116491","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.538497+00:00","generated_at":"2026-06-22T00:35:04.467659+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva Q3 gross royalties $65.6M, income before taxes surges to $286.4M on TRC sale gain","bullets":["Gross royalty revenues of $65.6M (flat YoY) from RELVAR/BREO ($55.7M) and ANORO ($9.9M).","Income before taxes rose to $286.4M from $123.2M, primarily due to gain from sale of 15% TRC interest to Royalty Pharma for $282M.","Completed acquisitions: Entasis for $42.4M and La Jolla for net cash $150.5M, expanding hospital/infectious disease portfolio.","Board authorized new $100M share repurchase program; no termination date, management discretion.","GSK reported RELVAR/BREO net sales $371.1M (+3% YoY) and ANORO $153.0M (-15% YoY), reflecting currency and pricing headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116491","json":"https://secwatch.observer/filing/0001104659-22-116491.json","markdown":"https://secwatch.observer/filing/0001104659-22-116491.md","text":"https://secwatch.observer/filing/0001104659-22-116491.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922116491/0001104659-22-116491-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465922116491/tm2230075d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:35:04.467659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}